VHL, the story of a tumour suppressor gene (Q34455226)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	VHL, the story of a tumour suppressor gene	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

VHL, the story of a tumour suppressor gene (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

3

object named as

Eamonn R Maher

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Lucy Gossage

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Tim Eisen

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

1 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Nature Reviews Cancer

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

55-64

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Über eine sehr seltene Erkrankung der Netzhaut

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

ZUR FRAGE DER ANGIOMATOSIS RETINae UND IHRER HIRNKOMPLIKATIONEN

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

von Hippel-Lindau disease: a clinical and scientific review

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Tumour suppression by the human von Hippel-Lindau gene product

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Integrated molecular analysis of clear-cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

A conserved family of prolyl-4-hydroxylases that modify HIF

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Oxygen sensing, homeostasis, and disease

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Emerging roles of microRNAs in the molecular responses to hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Hypoxia-inducible factor 2 regulates hepatic lipid metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Software and database for the analysis of mutations in the VHL gene

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Genotype-phenotype correlations in von Hippel-Lindau disease.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Mutations in the VHL gene in sporadic apparently congenital polycythemia

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W).

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Genetic basis of congenital erythrocytosis: mutation update and online databases

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Acute postnatal ablation of Hif-2alpha results in anemia

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Mutation and cancer: statistical study of retinoblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Alterations in VHL as potential biomarkers in renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

BAP1 loss defines a new class of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Germ-line mutations in nonsyndromic pheochromocytoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Molecular genetics of clear-cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Comprehensive molecular characterization of clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Treatment selection in metastatic renal cell carcinoma: expert consensus

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Allosteric inhibition of hypoxia inducible factor-2 with small molecules

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Exploring the limits of benzimidazole DNA-binding oligomers for the hypoxia inducible factor (HIF) site.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Molecular pathways in renal cell carcinoma--rationale for targeted treatment

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The concept of synthetic lethality in the context of anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

pVHL function is essential for endothelial extracellular matrix deposition.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

VHL loss causes spindle misorientation and chromosome instability.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Primary cilium formation requires von hippel-lindau gene function in renal-derived cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Binding of natively unfolded HIF-1alpha ODD domain to p53

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

p53 stabilization and transactivation by a von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The positive regulation of p53 by the tumor suppressor VHL.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

21 January 2018

Specific genetic change in tumors associated with von Hippel-Lindau disease

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Genotype-phenotype correlations in VHL exon deletions

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Von hippel-lindau disease and erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter

1 reference

https://api.crossref.org/works/10.1038%2FNRC3844

31 March 2020

[Results of mutation analyses of von Hippel-Lindau disease gene in Japanese patients: comparison with results in United States and United Kingdom]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Catalogue of Somatic Mutations in Cancer (COSMIC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic analysis of von Hippel-Lindau disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Von Hippel-Lindau disease in a Newfoundland kindred

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Function in protein folding of TRiC, a cytosolic ring complex containing TCP-1 and structurally related subunits

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A rationally designed small molecule that inhibits the HIF-1alpha-ARNT heterodimer from binding to DNA in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/25533676

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRC3844

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34455226&oldid=2196649264"